Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker RNST
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Jonathan A. Levy Director | RNST Renasant Corporation | Buy | 2,000 | $41.06 | $82.1K Buy | Form 4 ↗ |
| Aug 3, 2026 | Edward Robinson McGraw Director | RNST Renasant Corporation | Sale | 35,000 | $43.88 | $1.5M Sale | Form 4 ↗ |
| May 29, 2026 | Connie L. Engel Director | RNST Renasant Corporation | Sale | 1,257 | $40.90 | $51.4K Sale | Form 4 ↗ |
| May 19, 2026 | Albert J. Dale III Director | RNST Renasant Corporation | Sale | 1,650 | $39.80 | $65.7K Sale | Form 4 ↗ |
| May 14, 2026 | C. Mitchell Waycaster Executive Vice Chairman, Director | RNST Renasant Corporation | Sale | 12,704 | $39.50 | $501.8K Sale | Form 4 ↗ |
| Mar 4, 2026 | Kelly Hutcheson EVP/Chief Accounting Officer | RNST Renasant Corporation | Sale | 1,350 | $38.65 | $52.2K Sale | Form 4 ↗ |
| Feb 13, 2026 | Cole M Ray Jr SEVP and Executive Advisor, Director | RNST Renasant Corporation | Sale | 1,060 | $40.63 | $43.1K Sale | Form 4 ↗ |
| Feb 13, 2026 | Cole M Ray Jr SEVP and Executive Advisor, Director | RNST Renasant Corporation | Sale | 1,162 | $40.63 | $47.2K Sale | Form 4 ↗ |
| Feb 13, 2026 | Cole M Ray Jr SEVP and Executive Advisor, Director | RNST Renasant Corporation | Sale | 17,778 | $40.63 | $722.3K Sale | Form 4 ↗ |
| Feb 2, 2026 | Mark Jeanfreau EVP/General Counsel | RNST Renasant Corporation | Sale | 6,000 | $37.88 | $227.3K Sale | Form 4 ↗ |
| Jan 30, 2026 | James C. Mabry IV EVP and CFO | RNST Renasant Corporation | Sale | 12,500 | $37.83 | $472.9K Sale | Form 4 ↗ |
| Nov 11, 2025 | Jonathan A. Levy Director | RNST Renasant Corporation | Buy | 2,000 | $34.79 | $69.6K Buy | Form 4 ↗ |
| Aug 1, 2025 | Jonathan A. Levy Director | RNST Renasant Corporation | Buy | 2,000 | $35.64 | $71.3K Buy | Form 4 ↗ |
| Feb 21, 2025 | Kelly Hutcheson EVP/Chief Accounting Officer | RNST Renasant Corporation | Sale | 1,310 | $36.72 | $48.1K Sale | Form 4 ↗ |
| Nov 6, 2024 | John Creekmore Director | RNST Renasant Corporation | Sale | 3,000 | $38.00 | $114.0K Sale | Form 4 ↗ |
15 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:19 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances